Alizapride: Difference between revisions
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
No edit summary |
||
| Line 1: | Line 1: | ||
<div style="float: right;"> | |||
[[File:Alizapride.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | |||
| | |||
__NOTOC__ | |||
{{SI}} | |||
'''Alizapride''' is a [[dopamine antagonist]] with [[prokinetic]] and [[antiemetic]] effects used in the treatment of [[nausea]] and [[vomiting]], including [[postoperative nausea and vomiting]]. It is structurally related to [[metoclopramide]].<ref>{{cite journal |author=Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M |title=Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial |journal=Cancer Chemother Pharmacol |volume=22 |issue=4 |pages=316–20 |year=1988 |pmid=3048762 |doi=}}</ref> | {{CMG}} | ||
==Overview== | |||
'''Alizapride''' ('''Litican''', '''Plitican''', '''Superan''', '''Vergentan''') is a [[dopamine antagonist]] with [[prokinetic]] and [[antiemetic]] effects used in the treatment of [[nausea]] and [[vomiting]], including [[postoperative nausea and vomiting]]. It is structurally related to [[metoclopramide]] and other [[benzamide]]s.<ref>{{cite journal |author=Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M |title=Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial |journal=Cancer Chemother Pharmacol |volume=22 |issue=4 |pages=316–20 |year=1988 |pmid=3048762 |doi=10.1007/bf00254238}}</ref> | |||
== | == See also == | ||
* [[Antiemetic]] | |||
* [[Benzamide]] | |||
[[File:Alizapride1.png|thumb|none|400px|This image is provided by the National Library of Medicine.] | |||
== References == | |||
{{Reflist|2}} | |||
{{Antiemetics}} | |||
{{Propulsives}} | |||
{{Dopaminergics}} | |||
[[Category:Antiemetics]] | [[Category:Antiemetics]] | ||
[[Category:Dopamine antagonists]] | [[Category:Dopamine antagonists]] | ||
[[Category:Motility stimulants]] | [[Category:Motility stimulants]] | ||
[[Category: | [[Category:Phenol ethers]] | ||
[[Category:Benzotriazoles]] | |||
[[Category:Benzamides]] | |||
[[Category:Pyrrolidines]] | |||
[[Category:Drug]] | |||
Revision as of 14:33, 8 April 2015
|
WikiDoc Resources for Alizapride |
|
Articles |
|---|
|
Most recent articles on Alizapride |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Alizapride at Clinical Trials.gov Clinical Trials on Alizapride at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Alizapride
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Alizapride Discussion groups on Alizapride Patient Handouts on Alizapride Directions to Hospitals Treating Alizapride Risk calculators and risk factors for Alizapride
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Alizapride |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Alizapride (Litican, Plitican, Superan, Vergentan) is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide and other benzamides.[1]
See also
[[File:Alizapride1.png|thumb|none|400px|This image is provided by the National Library of Medicine.]
References
- ↑ Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M (1988). "Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial". Cancer Chemother Pharmacol. 22 (4): 316–20. doi:10.1007/bf00254238. PMID 3048762.